NVIDIA's BioNeMo platform has secured partnerships with US-based Eli Lilly and Massachusetts laboratory equipment maker Thermo Fisher Scientific to accelerate AI-driven drug discovery infrastructure.1 The collaborations extend to biotech innovators including California's Terray, Germany's Apheris, and TetraScience, focusing on foundation model development for pharmaceutical research across transatlantic operations.1
The platform orchestrates AI workflows connecting laboratory automation with machine learning models. Pharmaceutical companies use the system to run iterative experiments where AI predictions guide physical lab work, creating feedback loops that refine molecular predictions.1 This lab-in-the-loop approach differs from pure computational methods prevalent in academic research.
Five biotech companies have launched production tools on BioNeMo. San Carlos-based Natera, UK's Basecamp Research EDEN system, French precision medicine firm Owkin's OwkinZero, Edison's Kosmos, and Boltz Lab released tools within the ecosystem.1 The geographic spread from Silicon Valley to European biotech hubs indicates cross-border adoption.
Eli Lilly's participation signals validation from a pharmaceutical giant with global manufacturing footprint spanning 18 countries. Thermo Fisher's involvement brings laboratory equipment integration, connecting physical instrumentation used in research facilities worldwide to AI modeling systems. This hardware-software bridge enables automated experimental design where models propose tests and lab robots execute them.
Terray specializes in small molecule discovery, Germany's Apheris provides federated learning infrastructure for sensitive health data under GDPR regulations, and TetraScience focuses on lab data harmonization. Their combined capabilities address bottlenecks in data quality, privacy constraints, and experimental throughput facing international pharmaceutical collaborations.
NVIDIA positions BioNeMo as infrastructure rather than end-user software. The platform provides pre-trained models for protein structure, molecular properties, and biological sequences. Partners customize these foundations for specific therapeutic areas or screening workflows aligned with regional regulatory requirements.
The pharmaceutical industry has historically struggled to operationalize AI research across borders. Academic breakthroughs often fail to integrate with regulated manufacturing pipelines that span multiple jurisdictions. Multiple concurrent product launches within months suggest BioNeMo has reached critical mass where each new tool increases ecosystem value globally.
